A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis

Trial Profile

A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone; Dexamethasone
  • Indications Amyloidosis
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Dec 2016 Updated results (data cutoff 23 Jun 2016) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Jul 2016 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.
    • 12 Jul 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top